Primary disease(s) Source Study design Quality rating No. of patients Dosage Controlled group Outcome measure Outcome
Adult-onset Still’s Disease Kaneko et al. 2018[25] Randomized controlled trial 1 27 8 mg/kg/4 weeks for 40 weeks Placebo Systemic feature score, glucocorticoid dose The least squares means for change in systemic feature score at week 12 were 4.1 in the tocilizumab group and 2.3 in the placebo group (p=0.003). The dose of glucocorticoids at week 12 decreased by 46.2% in the tocilizumab group and 21.0% in the placebo group (p=0.017).
Sjögren’s Syndrome Felten et al. 2020[26] Randomized controlled trial 1 110 8 mg/kg/4 weeks for 6 months Placebo ESSDAI score ESSDAI score decreased in tocilizumab group
Systemic Scleroderma
Khanna et al. 2016[27]
Randomized controlled trial
1
87
162 mg/ week for 48 weeks
Placebo
mRSS, VAS score, FACIT-fatigue scores.
mRSS improved, VAS score and FACIT-fatigue scores had favourable response.
Neuromyelitis Optic Spectrum Disease Zhang et al.2020[28] Randomized controlled trial 1 118 8 mg/kg/4 weeks for 60 weeks Azathioprine Median time to the first relapse The median time to first relapse was also longer in the tocilizumab group than the azathioprine group
Takayasu Arteritis
Nakaoka et al. 2020[29]
Randomized controlled trial
1
36
162 mg/ week for 96 weeks or longer
Placebo
Mean 36-Item Short Form Health Survey, glucocorticoid dose
Mean 36-Item Short Form Health Survey 7 of 8 domain scores were clinically improved from baseline and maintained over 96 weeks. The dose of glucocorticoid was less than a half before treatment.
Systemic Lupus Erythematosus
Lllei et al. 2018[30]
Open-label controlled trial
2
16
2 mg/kg [n=4], 4 mg/kg [n=6], 8 mg/kg [n=6], for 12 weeks
Different doseage group
SELENA-SLEDAI score
Anti-dsDNA antibody levels decreased, IgG levels decreased, circulating plasma cells decreased
Relapsing Polychondritis Moulis et al. 2018[31] Cohort study 3 43 Not clear TNF inhibitors, anakinra, rituximab, abatacept Complete response (CR). Tocilizumab was highly effective for almost all features of RP and decreased doseage of glucosteroid significantly.
Dermatomyositis Kondo et al. 2014[32] Case Report 5 1 Not clear N/A Serum CK level Serum CK level decreased
Psoriatic Arthritis
Madureira et al.[33]
Case series
5
3
8 mg/kg/4 weeks (Case 1: 12 months; Case 2: 48 months; Case 3: 37 months) Case 1,2: adalimumab Case 3: rituximab PASI, CRP, DAS, TJC, SJC, HAQ
All measure items decreased
Systemic Vasculitis Sakai et al. 2017[34] Case series 5 2 8 mg/kg/4 weeks for 2 weeks N/A Prednisolone dose Prednisolone dose decreased significantly
Quality rating scheme is modified from the Oxford Centre of Evidence-Based Medicine for ratings of individual studies: (1) properly powered and conducted randomized clinical trial; systematic review with meta-analysis; (2) well-designed controlled trial without randomization; prospective comparative cohort trial; (3) case-control studies; retrospective cohort study; (4) case series with or without intervention; cross-sectional study; (5) opinion of respected authorities; case reports. Quality rating scheme is modified from the Oxford Centre of Evidence-Based Medicine for ratings of individual studies: (1) properly powered and conducted randomized clinical trial; systematic review with meta-analysis; (2) well-designed controlled trial without randomization; prospective comparative cohort trial; (3) case-control studies; retrospective cohort study; (4) case series with or without intervention; cross-sectional study; (5) opinion of respected authorities; case reports. Quality rating scheme is modified from the Oxford Centre of Evidence-Based Medicine for ratings of individual studies: (1) properly powered and conducted randomized clinical trial; systematic review with meta-analysis; (2) well-designed controlled trial without randomization; prospective comparative cohort trial; (3) case-control studies; retrospective cohort study; (4) case series with or without intervention; cross-sectional study; (5) opinion of respected authorities; case reports. Quality rating scheme is modified from the Oxford Centre of Evidence-Based Medicine for ratings of individual studies: (1) properly powered and conducted randomized clinical trial; systematic review with meta-analysis; (2) well-designed controlled trial without randomization; prospective comparative cohort trial; (3) case-control studies; retrospective cohort study; (4) case series with or without intervention; cross-sectional study; (5) opinion of respected authorities; case reports. Quality rating scheme is modified from the Oxford Centre of Evidence-Based Medicine for ratings of individual studies: (1) properly powered and conducted randomized clinical trial; systematic review with meta-analysis; (2) well-designed controlled trial without randomization; prospective comparative cohort trial; (3) case-control studies; retrospective cohort study; (4) case series with or without intervention; cross-sectional study; (5) opinion of respected authorities; case reports. Quality rating scheme is modified from the Oxford Centre of Evidence-Based Medicine for ratings of individual studies: (1) properly powered and conducted randomized clinical trial; systematic review with meta-analysis; (2) well-designed controlled trial without randomization; prospective comparative cohort trial; (3) case-control studies; retrospective cohort study; (4) case series with or without intervention; cross-sectional study; (5) opinion of respected authorities; case reports. Quality rating scheme is modified from the Oxford Centre of Evidence-Based Medicine for ratings of individual studies: (1) properly powered and conducted randomized clinical trial; systematic review with meta-analysis; (2) well-designed controlled trial without randomization; prospective comparative cohort trial; (3) case-control studies; retrospective cohort study; (4) case series with or without intervention; cross-sectional study; (5) opinion of respected authorities; case reports. Quality rating scheme is modified from the Oxford Centre of Evidence-Based Medicine for ratings of individual studies: (1) properly powered and conducted randomized clinical trial; systematic review with meta-analysis; (2) well-designed controlled trial without randomization; prospective comparative cohort trial; (3) case-control studies; retrospective cohort study; (4) case series with or without intervention; cross-sectional study; (5) opinion of respected authorities; case reports. Quality rating scheme is modified from the Oxford Centre of Evidence-Based Medicine for ratings of individual studies: (1) properly powered and conducted randomized clinical trial; systematic review with meta-analysis; (2) well-designed controlled trial without randomization; prospective comparative cohort trial; (3) case-control studies; retrospective cohort study; (4) case series with or without intervention; cross-sectional study; (5) opinion of respected authorities; case reports.